Please assess the completion status of the following clinical trial:

Trial Title: Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Phase I:~  * Histologically or cytologically confirmed solid tumor~    * Metastatic OR locally advanced unresectable disease~   * No curative therapy exists~ * Measurable or evaluable disease~    * Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm with conventional techniques OR ≥ 10 mm with spiral CT scan~ * No known brain metastases~* Phase II:~  * Histologically or cytologically confirmed colorectal cancer~    * Metastatic OR locally advanced unresectable disease~ * Measurable disease (as defined in phase I)~ * No tumor involving major blood vessels~ * No evidence of CNS disease, including primary brain tumor or brain metastases~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Life expectancy ≥ 12 weeks~* Absolute neutrophil count (ANC) ≥ 1,500/mm\^3~  * ANC \< 1,500/mm\^3 allowed, if in the opinion of the investigator, this represents an ethnic or racial variation of normal~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin \> 10.0 g/dL~* Bilirubin ≤ 1.5 mg/dL~* AST/ALT ≤ 2 times upper limit of normal (ULN)~* Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min~* Urine protein:creatinine ratio \< 1.0 OR protein \< 1 g by 24-hour urine collection (phase II)~* PT/INR ≤ 1.5 unless on full-dose anticoagulants (phase II)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile female patients must use effective double-barrier contraception during and for 28 days (phase I) or 3 months (phase II) after completion of study treatment~* Fertile male patients must use effective contraception during and for 6 months after completion of study treatment~* No history of allergic reaction attributed to compounds of similar chemical or biologic composition to capecitabine, irinotecan hydrochloride, oxaliplatin, or bevacizumab~* No other uncontrolled illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness or social situation that would preclude study compliance~* No cardiac ischemia within the past 6 months (phase I)~* No New York Heart Association class II-IV congestive heart failure or symptomatic arrhythmia (phase II)~* No arterial thrombotic events within the past 6 months including, but not limited to, any of the following (phase II):~  * Transient ischemic attack~ * Cerebrovascular accident~ * Unstable angina or angina requiring surgical or medical intervention~ * Myocardial infarction~* No clinically significant peripheral vascular disease (phase II)~* No history of hypertension unless well controlled (\< 150/90 mm Hg) on an antihypertensive regimen (phase II)~* No evidence of bleeding diathesis or coagulopathy (phase II)~* No gastrointestinal (GI) perforation, abdominal fistula, or intra-abdominal abscess within the past 30 days (phase II)~* No significant history of bleeding events (phase II)~  * Patients with a history of significant bleeding episodes (e.g., hemoptysis or upper or lower GI bleeding) within the past 6 months are not eligible unless the source of bleeding has been resected~* No significant traumatic injury within the past 28 days (phase II)~* No serious or nonhealing wound, ulcer, or bone fracture (phase II)~* No peripheral neuropathy \> grade 1~PRIOR CONCURRENT THERAPY:~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered (phase I)~* At least 2 weeks since prior immunotherapy or biologic therapy and recovered (phase I)~* No prior treatment for advanced or metastatic colorectal cancer (phase II)~* More than 12 months since prior adjuvant chemotherapy and/or biologic therapy (e.g., bevacizumab or cetuximab) and recovered (phase II)~* At least 4 weeks since prior radiotherapy and recovered~* No prior radiotherapy to the only site of measurable disease unless there is measurable disease progression within the radiation port after completion of radiotherapy~* No prior radiotherapy to ≥ 20% of the bone marrow~* More than 28 days since prior major surgical procedure\* or open biopsy and recovered (phase II)~* More than 14 days since prior minor surgery\* and recovered (phase II)~* Concurrent full-dose anticoagulation (e.g., warfarin) allowed provided the following criteria are met (phase II):~  * Patient has an in-range INR (between 2 and 3) and is on a stable dose of oral anticoagulants or a stable dose of low molecular weight heparin~ * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., known varices)~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent investigational agents~* No concurrent sargramostim (GM-CSF) NOTE: \*Insertion of a vascular device is not considered major or minor surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy